Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

PRRT

  • Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumors
    You have access
    Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of 177Lu-DOTATATE in Neuroendocrine Tumors
    Lisa Bodei, Nitya Raj, Richard K. Do, Audrey Mauguen, Simone Krebs, Diane Reidy-Lagunes and Heiko Schöder
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 567-573; DOI: https://doi.org/10.2967/jnumed.122.264363
  • You have access
    Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center
    Ken Herrmann, Luca Giovanella, Andrea Santos, Jonathan Gear, Pinar Ozgen Kiratli, Jens Kurth, Ana M. Denis-Bacelar, Roland Hustinx, Marianne Patt, Richard L. Wahl, Diana Paez, Francesco Giammarile, Hossein Jadvar, Neeta Pandit-Taskar, Munir Ghesani and Jolanta Kunikowska
    Journal of Nuclear Medicine December 1, 2022, 63 (12) 1836-1843; DOI: https://doi.org/10.2967/jnumed.122.264321
  • Safety of Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease
    You have access
    Safety of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease
    Shahad Alsadik, Gopinath Gnanasegaran, Luohai Chen, Dalvinder Mandair, Christos Toumpanakis, Martyn Caplin and Shaunak Navalkissoor
    Journal of Nuclear Medicine October 1, 2022, 63 (10) 1503-1508; DOI: https://doi.org/10.2967/jnumed.121.263056
  • Targeted <strong>α</strong>-Emitter Therapy with <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial
    You have access
    Targeted α-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial
    Ebrahim S. Delpassand, Izabela Tworowska, Rouzbeh Esfandiari, Julien Torgue, Jason Hurt, Afshin Shafie and Rodolfo Núñez
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 1326-1333; DOI: https://doi.org/10.2967/jnumed.121.263230
  • 
    Intraarterial Administration Boosts <sup>177</sup>Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients
    You have access
    Intraarterial Administration Boosts 177Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients
    Evert-Jan P.A. Vonken, Rutger C.G. Bruijnen, Tom J. Snijders, Tatjana Seute, Marnix G.E.H. Lam, Bart de Keizer and Arthur J.A.T. Braat
    Journal of Nuclear Medicine March 1, 2022, 63 (3) 406-409; DOI: https://doi.org/10.2967/jnumed.121.262491
  • Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma
    You have access
    Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma
    Justin Ferdinandus, Wolfgang P. Fendler, Katharina Lueckerath, Christoph Berliner, Sabine Kurzidem, Eva Hadaschik, Joachim Klode, Lisa Zimmer, Elisabeth Livingstone, Dirk Schadendorf, Ken Herrmann, Juergen C. Becker and Selma Ugurel
    Journal of Nuclear Medicine March 1, 2022, 63 (3) 396-398; DOI: https://doi.org/10.2967/jnumed.121.262344
  • Quantitative <sup>68</sup>Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATE
    You have access
    Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
    Claudia Ortega, Rebecca K.S. Wong, Josh Schaefferkoetter, Patrick Veit-Haibach, Sten Myrehaug, Rosalyn Juergens, David Laidley, Reut Anconina, Amy Liu and Ur Metser
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1406-1414; DOI: https://doi.org/10.2967/jnumed.120.256727
  • Addition of <sup>131</sup>I-MIBG to PRRT (<sup>90</sup>Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
    Open Access
    Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
    David L. Bushnell, Kellie L. Bodeker, Thomas M. O’Dorisio, Mark T. Madsen, Yusuf Menda, Stephen Graves, Gideon K.D. Zamba and M. Sue O’Dorisio
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1274-1277; DOI: https://doi.org/10.2967/jnumed.120.254987
  • You have access
    Inflammation-Based Index and 68Ga-DOTATOC PET–Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with 90Y-DOTATOC
    Elin Pauwels, Sofie Van Binnebeek, Vincent Vandecaveye, Kristof Baete, Hubert Vanbilloen, Michel Koole, Felix M. Mottaghy, Karin Haustermans, Paul M. Clement, Kristiaan Nackaerts, Eric Van Cutsem, Chris Verslype and Christophe M. Deroose
    Journal of Nuclear Medicine July 1, 2020, 61 (7) 1014-1020; DOI: https://doi.org/10.2967/jnumed.119.236935
  • You have access
    Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients
    Else A. Aalbersberg, Daphne M.V. Huizing, Iris Walraven, Berlinda J. de Wit-van der Veen, Harshad R. Kulkarni, Aviral Singh, Marcel P.M. Stokkel and Richard P. Baum
    Journal of Nuclear Medicine September 1, 2019, 60 (9) 1259-1265; DOI: https://doi.org/10.2967/jnumed.118.224386

Pages

  • Next
  • 1
  • 2
  • 3
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire